Media headlines about GTX (NASDAQ:GTXI) have trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GTX earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.6164399830149 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of GTX (NASDAQ:GTXI) opened at $14.31 on Friday. The firm has a market cap of $305.89, a P/E ratio of -8.13 and a beta of 1.77. GTX has a 52-week low of $2.73 and a 52-week high of $14.39.
GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). equities research analysts anticipate that GTX will post -1.61 earnings per share for the current year.
GTXI has been the subject of several recent research reports. Zacks Investment Research raised GTX from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. Stifel Nicolaus began coverage on shares of GTX in a research report on Thursday, November 9th. They set a “buy” rating for the company. Robert W. Baird began coverage on shares of GTX in a research report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 target price for the company. Finally, BidaskClub raised shares of GTX from a “buy” rating to a “strong-buy” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $17.00.
In other GTX news, insider Jason T. Shackelford sold 3,090 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $35,009.70. Following the transaction, the insider now directly owns 31,111 shares in the company, valued at approximately $352,487.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Henry Patton Doggrell sold 4,965 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $56,253.45. Following the transaction, the vice president now owns 54,804 shares in the company, valued at $620,929.32. The disclosure for this sale can be found here. Insiders have sold a total of 15,364 shares of company stock valued at $174,074 in the last three months. Insiders own 41.20% of the company’s stock.
WARNING: This piece of content was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/28/gtx-gtxi-earning-somewhat-positive-media-coverage-study-shows.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GTX and related companies with MarketBeat.com’s FREE daily email newsletter.